Kaleido Biosciences, Inc. (KLDO)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jan 17, 2025, 3:00 PM EST
Kaleido Biosciences Revenue
In the year 2021, Kaleido Biosciences had annual revenue of $1.10M with 13.23% growth. Kaleido Biosciences had revenue of $492.00K in the quarter ending December 31, 2021, with 102.47% growth.
Revenue
1.10M
Revenue Growth
+13.23%
P/S Ratio
0.00
Revenue / Employee
14.53K
Employees
76
Market Cap
43.00
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
Silence Therapeutics | 21.77M |
Kaleido Biosciences News
- 3 years ago - Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why - Benzinga
- 3 years ago - Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress - GlobeNewsWire
- 3 years ago - Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions - GlobeNewsWire
- 3 years ago - Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer - GlobeNewsWire
- 3 years ago - Kaleido Biosciences Reports Third Quarter 2021 Financial Results - GlobeNewsWire
- 3 years ago - Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit - GlobeNewsWire
- 3 years ago - Why Did Kaleido Shares Plunge 10% On Tuesday? - Benzinga
- 3 years ago - Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021 - GlobeNewsWire